| Harrison Healthcare Center | |
| 150 Beechmont Dr, Corydon, Indiana 47112 | |
| (812) 738-0550 | |
| Name | Harrison Healthcare Center |
|---|---|
| Location | 150 Beechmont Dr, Corydon, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 92 |
| Occupancy Rate | 81.52% |
| Medicare ID (CCN) | 155657 |
| Legal Business Name | Columbus Regional Hospital |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1033531462 |
| Organization Name | ADAMS COUNTY MEMORIAL HOSPITAL |
| Doing Business As | KINDRED TRANSITIONAL CARE AND REHABILITATION-HARRISON |
| Address | 150 Beechmont Dr Ne, Corydon, IN 47112 |
| Phone Number | 812-738-0550 |
News Archive
Vitamin D supplementation during pregnancy may lead to stronger bones in babies born during the winter months, a new Southampton study has shown.
Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.
In a paper published in the November 9 issue of The Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine and University of Washington describe in deeper detail the pathology of a devastating neurological disorder, but also reveal new cellular targets for possibly slowing its development.
W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.
Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Vitamin D supplementation during pregnancy may lead to stronger bones in babies born during the winter months, a new Southampton study has shown.
Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.
In a paper published in the November 9 issue of The Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine and University of Washington describe in deeper detail the pathology of a devastating neurological disorder, but also reveal new cellular targets for possibly slowing its development.
W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.
Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.47 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.38 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.52 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.43 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.53 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 16.41 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.85 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.68 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.17 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 61.08 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.43 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 25.18 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 21.93 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.96 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.9 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 85.51 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 83.67 | 82.93 |
News Archive
Vitamin D supplementation during pregnancy may lead to stronger bones in babies born during the winter months, a new Southampton study has shown.
Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.
In a paper published in the November 9 issue of The Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine and University of Washington describe in deeper detail the pathology of a devastating neurological disorder, but also reveal new cellular targets for possibly slowing its development.
W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.
Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.
› Verified 1 days ago
Indian Creek Healthcare Center Location: 240 Beechmont Dr, Corydon, Indiana 47112 Phone: (812) 738-8127 | |
Harrison Springs Health Campus Location: 871 Pacer Drive Nw, Corydon, Indiana 47112 Phone: (812) 738-0317 |